Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.
- Published In:
- International journal of obesity (2005), 48(12), 1684-1695 (2024)
- Database ID:
- RPEP-07703
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07703APA
Ala, Moein; Mohammad Jafari, Razieh; Dehpour, Ahmad Reza; Poursalehian, Mohammad. (2024). Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.. International journal of obesity (2005), 48(12), 1684-1695. https://doi.org/10.1038/s41366-024-01621-4
MLA
Ala, Moein, et al. "Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.." International journal of obesity (2005), 2024. https://doi.org/10.1038/s41366-024-01621-4
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide outcompetes long-acting insulin in managing type..." RPEP-07703. Retrieved from https://rethinkpeptides.com/research/ala-2024-tirzepatide-outcompetes-longacting-insulin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.